Jump Financial’s Fortress Biotech FBIO Stock Holding History

Jump Financial’s Portfolio FBIO Stock Details FBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,497	Closed	-$131K	–	1652
2021 Q4	$131K	Buy	+3,497	New	+$156K	0.01%	1189

Other funds holding FBIO

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SAM

Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return

CPWM LLC Seattle, Washington $1.06B AUM 14.49% 1-Year Est. Return

Jump Financial's FBIO Position: Q1 2022 in Review

Jump Financial sold out of Fortress Biotech (FBIO) in Q1 2022, closing a stake of 3,497 shares — an estimated $131K sold.

Jump Financial first reported a position in FBIO in Q4 2021 and held it in 1 quarter. The position peaked at $131K in Q4 2021. 79 funds tracked by Wall St. Rank hold FBIO as of Q1 2022.

Jump Financial reported no remaining Fortress Biotech position as of Q1 2022 after selling out during the quarter.
Jump Financial sold 3,497 Fortress Biotech shares in Q1 2022, an estimated $131K.
Jump Financial first reported a position in Fortress Biotech in Q4 2021 and held it in 1 quarter.
Jump Financial's Fortress Biotech position peaked at $131K in Q4 2021.
79 funds tracked by Wall St. Rank held Fortress Biotech as of Q1 2022.

Based on Jump Financial's 13F filing for Q1 2022, filed 12 May 2022.